Updated phase 2 DUBHE-C-204 trial data shows iparomlimab/tuvonralimab with chemotherapy, with or without bevacizumab, yields a 75.9% objective response rate in recurrent/metastatic cervical cancer.
The NK cell therapy field is experiencing significant growth, driven by its potential to address unmet needs in cancer treatment with safer, more targeted options.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.